Last reviewed · How we verify

NCT05081479

A Study of N-Acetylcysteine (N-AC) in People Receiving CAR T-cell Therapy for Lymphoma

Active, enrolled Phase 1 Last updated 4 November 2025
What this trial tests

Phase 1 trial testing N-Acetylcysteine in Lymphoma in 9 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
8 December 2021
Primary endpoint
21 October 2026
21 October 2026

Quick facts

Lead sponsorMemorial Sloan Kettering Cancer Center
PhasePhase 1
StatusActive, enrolled
Study typeINTERVENTIONAL
Allocationnon randomized
Designsequential
Maskingnone
Primary purposetreatment
Enrollment9
Start date8 December 2021
Primary completion21 October 2026
Estimated completion21 October 2026
Sites7 locations across United States

Drugs / interventions tested

Conditions studied

Sponsor

Memorial Sloan Kettering Cancer Center — full company profile →

Who can join

18 and older, any sex, with Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to test the safety of N-AC when given in combination with Yescarta to people with lymphoma. This study will test different doses of N-AC to find the highest dose that causes few or mild side effects in participants.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Ferroptosis in cancer: From molecular mechanisms to therapeutic strategies.
    Zhou Q, Meng Y, Li D, Yao L, et al · · 2024 · cited 439× · PMID 38453898 · DOI 10.1038/s41392-024-01769-5
  2. NAC, NAC, Knockin' on Heaven's door: Interpreting the mechanism of action of N-acetylcysteine in tumor and immune cells.
    Kalyanaraman B. · · 2022 · cited 72× · PMID 36242913 · DOI 10.1016/j.redox.2022.102497
  3. CAR T Cell Locomotion in Solid Tumor Microenvironment.
    Nguyen DT, Ogando-Rivas E, Liu R, Wang T, et al · · 2022 · cited 47× · PMID 35741103 · DOI 10.3390/cells11121974
  4. Oxidative Stress and Age-Related Tumors.
    Di Carlo E, Sorrentino C. · · 2024 · cited 33× · PMID 39334768 · DOI 10.3390/antiox13091109
  5. Combination strategies to optimize the efficacy of chimeric antigen receptor T cell therapy in haematological malignancies.
    Xiao X, Wang Y, Zou Z, Yang Y, et al · · 2022 · cited 20× · PMID 36091028 · DOI 10.3389/fimmu.2022.954235
  6. Lipotoxicity, lipid peroxidation and ferroptosis: a dilemma in cancer therapy.
    Ma C, Hu H, Liu H, Zhong C, et al · · 2025 · cited 17× · PMID 40285867 · DOI 10.1007/s10565-025-10025-7
  7. Metabolism and signaling crosstalk in glioblastoma progression and therapy resistance.
    Zarzuela L, Durán RV, Tomé M. · · 2025 · cited 9× · PMID 38105543 · DOI 10.1002/1878-0261.13571
  8. Dysfunctional mitochondria in ageing T cells: a perspective on mitochondrial quality control mechanisms.
    Luo L, Lechuga-Vieco AV, Sattentau C, Borsa M, et al · · 2025 · cited 5× · PMID 40883510 · DOI 10.1038/s44319-025-00536-z

Verify or expand the search:

Other trials of N-Acetylcysteine

Trials testing the same drug.

Other recruiting trials for Lymphoma

Currently open trials in the same condition.

Other Memorial Sloan Kettering Cancer Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05081479.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing